Niagen Bioscience Shares Inch Lower Despite Regulatory Designations for NB4168
Niagen Bioscience shares slipped modestly in pre-market trading despite the company receiving a Rare Pediatric Disease Designation from the U.S. FDA and an Orphan Medicinal Product Designation from the European Medicines Agency for NB4168, its investigational therapy for Ataxia Telangiectasia. The price movement appears to reflect an anticipated re…